IDEXX Laboratories (IDXX)
Provides veterinary diagnostics, reference laboratories, and practice software for connected clinical workflows.
Something off on this page? Send us feedback.
Sells in-clinic analyzers and consumables, rapid assays, reference-laboratory testing, veterinary software and imaging, plus smaller water and livestock diagnostics businesses. The Companion Animal Group produces most revenue, with instrument placements supporting recurring consumable demand.
Develops veterinary point-of-care instruments, consumables, rapid assays and imaging systems, while operating reference laboratories, telemedicine services and practice-management software. Companion Animal Group integrates these tools for companion-animal clinics; smaller activities serve biomedical research and human point-of-care diagnostics.
Most revenue comes from Companion Animal Group. Placements of proprietary in-clinic analyzers expand an installed base that supports recurring consumable demand, while laboratory testing, telemedicine and software extend the customer workflow. Water products detect microbiological contaminants; Livestock, Poultry and Dairy supplies herd-health and milk-safety tests.
Serves customers across major global regions, with the United States the largest market. Breadth across clinic testing, reference labs and information management supports an integrated diagnostic workflow. Results depend on companion-animal diagnostic demand, instrument placements and use, regulatory acceptance for certain tests, and continuity from sole- and single-source suppliers.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 11, 2026 | Barclays | Reiterate | Rating: —Target: $800 | Target: $710 |
| Jul 27, 2026 | UBS | Reiterate | Rating: —Target: $640 | Target: $620 |
| Apr 28, 2026 | UBS | Reiterate | Rating: —Target: $730 | Target: $640 |
| Feb 9, 2026 | Piper Sandler | Reiterate | Rating: —Target: — | Target: $750 |
| Feb 5, 2026 | Barclays | Reiterate | Rating: —Target: $850 | Target: $800 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $196.9M · Total debt $1.10B · Total assets $3.44B · Shareholders' equity $1.61B
- Revenue
- $1.22B
- Operating income
- $425.6M
- Net income
- $338.4M
No dividends on record.
| Institutions | 95.27% | 75.05M shares | |
|---|---|---|---|
| 1,328 holders · as of Jun 30, 2026 | |||
| Insiders | 0.26% | 205.7K shares | |
| 18 holders · as of Sep 9, 2026 | |||
| Strategic holders | 0.04% | 27.7K shares | |
| 1 holder · as of Feb 14, 2017 | |||
| Other | 4.43% | 3.49M shares | |
| remainder | |||
78.78M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 10.37% | 8.17M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.54% | 5.15M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 4.95% | 3.90M | as of Jun 30, 2026 |
State Street CorpInstitution | 4.76% | 3.75M | as of Jun 30, 2026 |
Invesco Ltd.Institution | 4.58% | 3.61M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 4, 2026 | Lawrence D. Kingsley | director | −2,203 | $532.08 |
| Mar 3, 2026 | Nimrata Hunt | officer: Executive Vice President | −1,758 | $634.57 |
| Feb 26, 2026 | Jonathan Jay Mazelsky | director, officer: President and CEO | −23,326 | $657.55 |
| Feb 26, 2026 | Nimrata Hunt | officer: Executive Vice President | −2,693 | $661.54 |
| Feb 17, 2026 | Sophie V. Vandebroek | director | −1,464 | $628.62 |
- Zoetis
Global animal health leader; Vetscan in-clinic analyzers compete head-to-head.
- Thermo Fisher Scientific
Named in IDEXX 10-K for LPD/water; Indiko chemistry for vet clinics.
- Neogen
Named in IDEXX 10-K; livestock diagnostics, genomics, and food safety overlap.
- Danaher
Hach water brand competes with Colilert; Beckman Coulter adjacent in lab.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| IDEXX Laboratories | $520.89 | −0.12% | $41.14B | 36.9 | 33.4 | 9.0 | +9.7% |
| Zoetis | $71.95 | −1.29% | $30.56B | 12.0 | 11.6 | 3.2 | +0.3% |
| Thermo Fisher Scientific | $658.95 | +0.06% | $243.49B | 35.4 | 25.1 | 5.3 | +10.5% |
| Neogen | $13.71 | −1.93% | $3.05B | — | 46.7 | 3.5 | −0.1% |
| Danaher | $221.17 | +0.04% | $155.44B | 39.3 | 25.0 | 6.2 | +5.5% |
| Median | 35.4 | 25.1 | 4.4 | +2.9% |